More can, and should, be done to improve the transparency and integrity of how local governments help fund Medicaid, but it’s ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

CMMI has spent more than a decade learning which organizations consistently deliver high-value care. The next step is to let ...

Community health workers are uniquely suited to help underresourced communities navigate structural barriers and mitigate the ...

Weeks earlier, the New York City Council passed the Guaranteeing Unbiased AI Regulation and Disclosure (GUARD) Act, which ...

As with so many core functions of public health, the future success of vaccine promotion research depends on the support of every institution: government, universities, and industry alike.

The surge in vaccine litigation is not simply a post-pandemic, temporary issue. It is a deeper erosion of the legal principles that have long supported public health authority.

Julia Adler-Milstein ( [email protected]) is an associate professor in the School of Information and School of Public Health (health management and policy) at the University of Michigan, in Ann Arbor.

The emergence of Lilly’s bundling strategy for Zepbound and Taltz reflects the unregulated state of patient assistance programs in the commercial market and the need for Congressional intervention.

CMS and states should look beyond simply expanding disclosure and improving standardization to also elevate antitrust safeguards.

For decades, mpox did not pose a threat to Americans, but that changed rapidly and repeatedly over the past five years.

Inhaled corticosteroid–long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; ...